Advanced in Hereditary Neuralgic Amyotrophy

Shahram Attarian

Marseille, FR 
Advanced in Hereditary Neuralgic Amyotrophy
Marseille, FR 
OverviewLocationsClinical Research

Overview

Shahram Attarian practices in Marseille, France. Mr. Attarian is rated as an Advanced expert by MediFind in the treatment of Hereditary Neuralgic Amyotrophy. His top areas of expertise are Pompe Disease, Primary Lateral Sclerosis, Cramp-Fasciculation Syndrome, Bone Marrow Aspiration, and Heart Transplant.

His clinical research consists of co-authoring 255 peer reviewed articles and participating in 7 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 2 articles in the study of Hereditary Neuralgic Amyotrophy.

Gender
Male

Locations

Marseille, France
Other Locations
France
Aix-en-provence, France
Creteil, France

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

7 Clinical Trials

An Open-label, Single Arm, Multi-centre, Phase II Study Investigating Safety, Tolerability, Efficacy, Pharmacodynamics and Pharmacokinetics of Imlifidase in Patients With Guillain-Barré Syndrome, in Comparison With Matched Control Patients
An Open-label, Single Arm, Multi-centre, Phase II Study Investigating Safety, Tolerability, Efficacy, Pharmacodynamics and Pharmacokinetics of Imlifidase in Patients With Guillain-Barré Syndrome, in Comparison With Matched Control Patients
Enrollment Status: Completed
Publish Date: April 09, 2025
Intervention Type: Drug
Study Drug: Imlifidase
Study Phase: Phase 2
International GBS Outcome Study (IGOS): a Prospective INC Study on Clinical and Biological Predictors of Disease Course and Outcome in Guillain-Barré Syndrome (GBS).
International GBS Outcome Study (IGOS): a Prospective INC Study on Clinical and Biological Predictors of Disease Course and Outcome in Guillain-Barré Syndrome (GBS).
Enrollment Status: Completed
Publish Date: December 12, 2024
A Multicenter, Interventional, Open-label Study to Monitor the Evolution of Motor Function in SMA Type II Adults Patients Treated With SPINRAZA®
A Multicenter, Interventional, Open-label Study to Monitor the Evolution of Motor Function in SMA Type II Adults Patients Treated With SPINRAZA®
Enrollment Status: Completed
Publish Date: September 20, 2024
Intervention Type: Other
Study Phase: Not Applicable
A Multi-center, Randomized, Double-blind, Placebo Controlled Phase III Study to Assess the Efficacy, Safety, and Tolerability of PXT3003 in Charcot-Marie-Tooth Type 1A (CMT1A)
A Multi-center, Randomized, Double-blind, Placebo Controlled Phase III Study to Assess the Efficacy, Safety, and Tolerability of PXT3003 in Charcot-Marie-Tooth Type 1A (CMT1A)
Enrollment Status: Active_not_recruiting
Publish Date: April 03, 2024
Intervention Type: Drug
Study Drug: (RS)-Baclofen, Naltrexone Hydrochloride and D-Sorbitol
Study Phase: Phase 3
A Phase III Study to Evaluate the Efficacy, Safety, and Tolerability of Immune Globulin Infusion 10% (Human) With Recombinant Human Hyaluronidase (HYQVIA/HyQvia) and Immune Globulin Infusion (Human), 10% (GAMMAGARD LIQUID/KIOVIG) for the Treatment of Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)
A Phase III Study to Evaluate the Efficacy, Safety, and Tolerability of Immune Globulin Infusion 10% (Human) With Recombinant Human Hyaluronidase (HYQVIA/HyQvia) and Immune Globulin Infusion (Human), 10% (GAMMAGARD LIQUID/KIOVIG) for the Treatment of Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)
Enrollment Status: Completed
Publish Date: May 24, 2023
Intervention Type: Biological
Study Drugs: HYQVIA, Intravenous Immunoglobulin G
Study Phase: Phase 3
Characterization of Sensory Neuropathies Associated With Anti-FGFR3 Antibodies
Characterization of Sensory Neuropathies Associated With Anti-FGFR3 Antibodies
Enrollment Status: Completed
Publish Date: February 10, 2023
Intervention Type: Other
A Multicenter Open-Label Study on the Safety and Efficacy of Deflazacort (Emflaza) in Subjects With Limb-Girdle Muscular Dystrophy 2I (LGMD2I)
A Multicenter Open-Label Study on the Safety and Efficacy of Deflazacort (Emflaza) in Subjects With Limb-Girdle Muscular Dystrophy 2I (LGMD2I)
Enrollment Status: Terminated
Publish Date: June 27, 2022
Intervention Type: Drug
Study Phase: Phase 3
View 6 Less Clinical Trials

254 Total Publications

REGISTRE SMA FRANCE: A nationwide observational registry of patients with spinal muscular atrophy in France.
REGISTRE SMA FRANCE: A nationwide observational registry of patients with spinal muscular atrophy in France.
Journal: Journal of neuromuscular diseases
Published: July 08, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Attarian's expertise for a condition
ConditionClose
    View All 15 Distinguished Conditions
    View All 11 Advanced Conditions
    View All 56 Experienced Conditions
    Want to save this expert for later?
    Sign Up
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile